Why the study?
Diabetic peripheral and autonomic neuropathies are common, frequently under-diagnosed complications associated with increased mortality, yet multiple clinical trials have failed and single-agent therapies demonstrate limited efficacy.
Population
Patients with diabetic peripheral neuropathy (DPN) and autonomic neuropathy (AN)
Design
Review
Authors
Loading...
Multifactorial risk reduction may slow DPN/AN progression with partial pain relief; leaves open more effective painful DPN therapies.
Multifactorial risk factor reduction and targeted therapy are essential for managing diabetic somatic and autonomic neuropathy, though current treatments for painful DPN have limited efficacy.
Azmi et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: